BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16247665)

  • 1. Excellent response of chemotherapy-resistant B-cell-type chronic lymphocytic leukemia with meningeal involvement to rituximab.
    Watanabe N; Takahashi T; Sugimoto N; Tanaka Y; Kurata M; Matsushita A; Maeda A; Nagai K; Nasu K
    Int J Clin Oncol; 2005 Oct; 10(5):357-61. PubMed ID: 16247665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo purging with rituximab prior to collection of stem cells for autologous transplantation in chronic lymphocytic leukemia.
    Berkahn L; Simpson D; Raptis A; Klingemann HG
    J Hematother Stem Cell Res; 2002 Apr; 11(2):315-20. PubMed ID: 11983102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome.
    Seipelt G; Böhme A; Koschmieder S; Hoelzer D
    Ann Hematol; 2001 Mar; 80(3):170-3. PubMed ID: 11320903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia.
    Perz J; Topaly J; Fruehauf S; Hensel M; Ho AD
    Leuk Lymphoma; 2002 Jan; 43(1):149-51. PubMed ID: 11908720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL.
    Klepfish A; Gilles L; Ioannis K; Rachmilewitz EA; Schattner A
    Ann N Y Acad Sci; 2009 Sep; 1173():865-73. PubMed ID: 19758239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ofatumumab in the treatment of chronic lymphocytic leukemia.
    Tsimberidou AM
    Drugs Today (Barc); 2010 Jul; 46(7):451-61. PubMed ID: 20683500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody therapy for chronic lymphocytic leukemia: a promising new modality.
    Lin TS; Moran M; Lucas M; Waymer S; Jefferson S; Fischer DB; Grever MR; Byrd JC
    Hematol Oncol Clin North Am; 2004 Aug; 18(4):895-913, ix-x. PubMed ID: 15325705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous manifestation of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL).
    Sokol L; Agosti SJ
    Am J Hematol; 2004 Feb; 75(2):107-9. PubMed ID: 14755378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meningeal involvement in B-cell chronic lymphocytic leukemia: report of two cases.
    Wang ML; Shih LY; Dunn P; Kuo MC
    J Formos Med Assoc; 2000 Oct; 99(10):775-8. PubMed ID: 11061073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Merkel cell carcinoma in a patient with B-cell chronic lymphocytic leukemia treated with cladribine and rituximab.
    Robak E; Biernat W; Krykowski E; Jeziorski A; Robak T
    Leuk Lymphoma; 2005 Jun; 46(6):909-14. PubMed ID: 16019537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
    Robak T
    Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Membranoproliferative glomerulonephritis and light-chain nephropathy in association with chronic lymphocytic leukemia.
    Mutluay R; Aki SZ; Erten Y; Konca C; Yagci M; Barit G; Sindel S
    Clin Nephrol; 2008 Dec; 70(6):527-31. PubMed ID: 19049712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab in chronic lymphocytic leukemia.
    Jaglowski SM; Byrd JC
    Semin Hematol; 2010 Apr; 47(2):156-69. PubMed ID: 20350663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Curative efficacy of fludarabine combined with rituximab and amifostine on aged patient with B-chronic lymphocytic leukemia].
    Liu Y; Zhu HL; Lu XC; Li SX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):989-92. PubMed ID: 17956676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
    Hallek M
    Am J Hematol; 2015 May; 90(5):446-60. PubMed ID: 25908509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab for chronic lymphocytic leukemia.
    Robak T
    Expert Opin Biol Ther; 2012 Apr; 12(4):503-15. PubMed ID: 22369284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab (anti-CD20 monoclonal antibody) administration in a young patient with resistant B-prolymphocytic leukemia.
    Vartholomatos G; Tsiara S; Christou L; Panteli A; Kaiafas P; Bourantas KL
    Acta Haematol; 1999; 102(2):94-8. PubMed ID: 10529513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.
    Bologna L; Gotti E; Manganini M; Rambaldi A; Intermesoli T; Introna M; Golay J
    J Immunol; 2011 Mar; 186(6):3762-9. PubMed ID: 21296976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of chronic lymphocytic leukemia with regimen of fludarabine, cyclophosphamide and rituximab].
    Gu WJ; Xu W; Qian SX; Wu YJ; Hong M; Chen LJ; Wu HX; Lu H; Qiu HX; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):938-42. PubMed ID: 18718095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.